Milestone Scientific Inc. (MLSS) AI Stock Analysis

Milestone Scientific Inc. specializes in the design, development, and global commercialization of innovative injection technologies across medical, dental, and cosmetic markets. The company operates in the United States and China through two main segments: Dental and Medical. Its dental lineup features the CompuDent and the STA Single Tooth Anesthesia System for local anesthetic delivery. In the medical market, the CompuFlo platform offers precise drug delivery, anesthetic administration, and fluid aspiration, supported by disposable injection handpieces. Its CompuMed system serves specialties such as plastic surgery, hair restoration, podiatry, dermatology, orthopedics, and colorectal procedures.

Milestone Scientific generated $9.0M in revenue in FY2025, reflecting 4.0% growth over FY2024 revenue of $8.6M. Gross margin stood at 70.5% in FY2025, compared to 74.6% in FY2024 and 69.1% in FY2023. Operating margin remained negative at -63.5% in FY2025, alongside a net loss of -$5.7M and EPS of -$0.06. From FY2020 through FY2025, revenue grew at a 5-year CAGR of 10.5%. Over the trailing twelve months ended June 30, 2026, revenue totaled $9.4M, with an operating margin of -37.4% and EPS of -$0.04. In the latest quarter ended June 30, 2026, quarterly revenue increased 22.3% year-over-year.

As of June 30, 2026, Milestone Scientific held $2.1M in cash and short-term investments against total debt of $615,703, resulting in net cash of $1.5M. Total assets stood at $8.3M and shareholders' equity was $3.5M. The company reported a current ratio of 1.85 and a debt-to-equity ratio of 0.18. Milestone Scientific used $2.9M in operating cash flow and recorded free cash flow of -$2.9M in FY2025, while capital expenditures totaled $15,124. Over five years, the company's share count increased by 33.9%.

Milestone Scientific trades at a forward P/E of 18.2x, compared to a median of 17.3x among its US-listed Healthcare peers. Its price-to-sales multiple is 3.1x, below the peer group median of 4.1x. The company has an enterprise value of $36.2M and a market capitalization of $29.6M, resulting in an EV-to-revenue ratio of 4.1x. Over the past year, MLSS shares declined 27.4%, trailing the S&P 500 return of 16.8%. Over a 5-year period, the stock fell 84.5% while the index gained 83.0%.

Wall Street coverage includes 1 Strong Buy and 1 Buy rating from 2 analysts. The mean price target is $1.25, which represents a 282.8% premium to the last closing price of $0.33. For the fiscal year ending December 31, 2026, analysts project revenue of $10.0M and EPS of -$0.04, reflecting an estimated 42.9% EPS improvement. For the following fiscal year, consensus estimates forecast revenue of $11.4M and EPS of -$0.04. Milestone Scientific beat EPS estimates 0 times over the last 4 quarters, with next earnings scheduled for November 12, 2026.

This page is an AI-written research summary of Milestone Scientific Inc. (MLSS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MLSS income statement, MLSS balance sheet, MLSS key metrics, MLSS analyst forecast, MLSS chart. See the MLSS stock overview for the latest quote and news.